Lilly shareholders to vote again on splitting CEO, board chair roles
For the third year in a row, an investor is proposing that the pharmaceutical company scrap the tradition of combining the role of chief executive officer and board chair.
Eli Lilly and Co.
Articles
Lilly plans $700M genetic medicine institute in Boston
The Indianapolis-based pharmaceutical company said the facility is part of its strategy to advance RNA-based therapeutics and builds on its acquisition of Prevail Therapeutics, a gene therapy company based in New York.
FDA gives early-use authorization to Lilly’s new COVID-19 antibody
The Indianapolis-based drugmaker said the antibody is effective against the omicron variant and it has already manufactured several hundred thousand doses. The deal calls for the federal government to pay Lilly more than $720 million.
Eli Lilly’s Alzheimer’s drug hits roadblock
The FDA has agreed to speed up review of donanemab, but the Centers for Medicare and Medicaid Services is moving to limit reimbursement for drugs in this class to only patients in clinical trials.
Lilly to supply 600K doses of new COVID-19 antibody to U.S., if OK’d by FDA
The deal calls for the federal government to pay Eli Lilly and Co. more than $720 million for the antibody, which the company said is effective against all COVID-19 variants.
Elements CEO stepping down after 17 years leading credit union
Lisa Schlehuber has served as CEO of Indianapolis-based Elements Financial since 2005. She’ll retire from the role in April, the credit union announced Wednesday.
Lilly seeking FDA approval for new antibody it says works against omicron
In December, the U.S. government paused distribution of Lilly’s two previous antibodies, saying they did not appear effective against the omicron variant.
Lilly to invest $1B in new manufacturing plant, create 600 jobs in North Carolina
Lilly said it selected Concord, North Carolina, because of the manufacturing technology experience of the local labor force; its proximity to universities with strong science, technology, engineering and math programs; and its access to major transportation infrastructure.
Michigan AG seeks to investigate Eli Lilly for high insulin prices
Indianapolis-based Eli Lilly and Co., one of three primary U.S. insulin manufacturers, said it was “deeply disappointed by the false accusations and inaccurate claims” made by the attorney general.
FDA expected to sharply restrict use of monoclonal antibodies made by Lilly, Regeneron
The Food and Drug Administration is poised as soon as Monday to restrict two monoclonal antibodies, saying the COVID-19 treatments should not be employed in any states because they are ineffective against the dominant omicron variant, according to two senior administration health officials.
U.S. sends states monoclonal antibodies that might not work against omicron
The federal government has resumed shipping all three monoclonal antibody treatments—including one made by Indianapolis-based Eli Lilly and Co.—that are authorized for early-stage COVID-19 to states despite evidence that two might be ineffective against the omicron variant.
Eli Lilly inks R&D pact with Canadian pharma company
Indianapolis-based Eli Lilly and Co. will make an initial $50 million payment to Entos Pharmaceuticals. Entos also could receive up to $400 million in potential milestone payments, as well as royalties, for successful products.
Lilly resumes political contributions to Republicans who voted against certifying election
The pharmaceutical giant has quietly returned to making political contributions to 14 Republican lawmakers who voted against certifying the 2020 election results, according to a report issued Monday by watchdog group Accountable.US.
U.S. government puts pause on Lilly’s COVID antibody therapies
The U.S. Department of Health and Human Services cited new data that shows the therapies are unlikely to be effective against the Omicron variant.
Lilly’s osteoporosis drug faces generic challenge from Indian drugmaker
Eli Lilly’s blockbuster drug for osteoporosis, Forteo, could face generic competition from Indian drugmaker Sun Pharmaceuticals if the company can get a federal judge to declare that a Lilly patent won’t be infringed.
Omicron may sideline Lilly, Regeneron antibody drugs against COVID-19
The companies say they can quickly develop new omicron-targeting antibodies, but those aren’t expected to launch for at least several months.
Lilly, Chinese firm to pursue therapies for metabolic disorders
Indianapolis-based Eli Lilly and Co. has inked a research collaboration and licensing agreement with Regor Therapeutics Group that could be worth up to $1.5 billion.
Biden pledges savings on insulin, other drugs for Americans
The biggest policy change—a system for Medicare to negotiate prices for prescription drugs—won’t begin to deliver lower costs until 2025, and then only for a selected set of 10 medicines, as well as insulin products.
Feds buy another $1.29B worth of Lilly antibody treatment for COVID-19
The purchase will amount to 614,000 doses of two drugs, bamlanivimab and etesevimab, that make up the drug-cocktail infusion, Lilly said.
Federal court blocks drug pricing enforcement action against Lilly
The ruling from Senior Judge Sarah Evans Barker also hinted that Congress needs to address the problems with the 340B Drug Pricing Program.